$411.7 M

INO Mkt cap, 16-Aug-2018

$26 M

Inovio Pharmaceuticals Revenue Q2, 2018
Inovio Pharmaceuticals Net income (Q2, 2018)-39 M
Inovio Pharmaceuticals EBIT (Q2, 2018)-37.9 M
Inovio Pharmaceuticals Cash, 30-Jun-201815.1 M

Inovio Pharmaceuticals Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

13.5 m10.5 m40.6 m8.5 m42.2 m

Revenue growth, %

(22%)288%(79%)

R&D expense

98.6 m

General and administrative expense

28.3 m

Operating expense total

125.9 m

EBIT

(19.5 m)(39.5 m)(34.3 m)(22.4 m)(83.6 m)

EBIT margin, %

(145%)(378%)(85%)(263%)(198%)

Interest income

8.6 k113.2 k194.5 k191.5 k1.6 m

Net Income

(66.1 m)(36.1 m)(29.1 m)(73.7 m)(88.2 m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

9.5 m2.4 m3.8 m1.8 m5.2 m5.3 m24.2 m8.1 m6.2 m12.5 m10.4 m20.4 m1.5 m26 m

R&D expense

5.4 m8.2 m9.6 m7 m9.4 m16.7 m16.1 m18.2 m19.6 m27 m24.5 m23.9 m24.6 m47 m

General and administrative expense

3.3 m4.1 m4.3 m3.2 m4.1 m4.7 m4.4 m5.4 m5.8 m5.8 m7.8 m6.2 m9.7 m16.9 m

Operating expense total

8.7 m12.4 m14 m10.2 m13.5 m20.4 m20.5 m23.6 m24.4 m32.7 m32.3 m30 m34.3 m63.9 m

EBIT

765.6 k(10 m)(10.2 m)(8.3 m)(8.4 m)(15.1 m)3.7 m(15.5 m)(18.2 m)(20.2 m)(21.9 m)(9.6 m)(32.7 m)(37.9 m)

EBIT margin, %

8%(424%)(267%)(453%)(162%)(286%)15%(191%)(294%)(161%)(211%)(47%)(2141%)(146%)

Interest income

46.8 k52.1 k69 k97.2 k138.3 k146.3 k215 k333.1 k341.1 k391.6 k340.3 k300 k312.5 k709.2 k

Income tax expense

1.8 m(2.2 m)(2.2 m)

Net Income

(30.9 m)(10.8 m)(10.7 m)(7.2 m)(10.6 m)(6.2 m)5.6 m(8 m)(18.7 m)(20.8 m)(32.4 m)(39 m)

Inovio Pharmaceuticals Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

33.7 m40.5 m57.6 m19.1 m23.8 m

Accounts Receivable

3.3 m2.8 m7.3 m15.8 m6 m

Inventories

637.4 k798 k917.3 k1.7 m

Current Assets

58.7 m98.9 m171.9 m124.6 m138.4 m

PP&E

18.3 m

Goodwill

10.1 m10.1 m10.1 m10.5 m10.5 m

Total Assets

88.3 m131.8 m213.8 m173.7 m187.2 m

Accounts Payable

5.4 m6.4 m13.1 m19.6 m23.3 m

Short-term debt

Current Liabilities

29 m14 m31.5 m43.8 m35.4 m

Long-term debt

Total Liabilities

50.3 m44.8 m

Additional Paid-in Capital

348.1 m443.3 m534 m556.7 m665.8 m

Retained Earnings

(295.8 m)(331.9 m)(361.1 m)(434.8 m)(523.4 m)

Total Equity

52.9 m111.5 m175.9 m123.4 m142.5 m

Financial Leverage

1.7 x1.2 x1.2 x1.4 x1.3 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

33.1 m98.8 m88.5 m70.7 m26.1 m70.3 m85.5 m41.6 m28.5 m23.3 m22.9 m23.9 m37.5 m15.1 m

Accounts Receivable

10.6 m2.7 m2.9 m1.6 m3.3 m5.6 m11 m11.2 m10.4 m17.5 m9.9 m7.5 m5.1 m1.7 m

Current Assets

57.9 m121.7 m112.9 m104.6 m87.3 m162.1 m184.1 m160.6 m148 m140.2 m106.8 m106.9 m123.8 m101.8 m

PP&E

17.5 m16.9 m

Goodwill

10.1 m10.1 m10.1 m10.1 m10.1 m10.1 m10.1 m10.1 m10.5 m10.5 m10.5 m10.5 m10.5 m10.5 m

Total Assets

88 m151.7 m142.2 m134.5 m117.9 m201.7 m230.8 m211.3 m204 m194.5 m153.3 m158.9 m173.7 m148.9 m

Accounts Payable

4 m5.3 m5.3 m4.7 m4.4 m6.1 m10.5 m12.1 m12.7 m16.2 m14.5 m16.5 m15.8 m12.6 m

Current Liabilities

20.4 m15.6 m11.6 m8.9 m8.2 m14.5 m18.3 m33.4 m35.5 m41.4 m40 m27.4 m51.4 m28.4 m

Total Liabilities

25.8 m22.5 m19.9 m17.5 m14.4 m20.7 m37.4 m40.1 m41.9 m47.6 m47.4 m35.3 m60.6 m37.4 m

Common Stock

207.6 k240.1 k60.3 k60.5 k60.7 k71.8 k72.2 k72.3 k73.5 k74 k74.6 k77.6 k90.7 k91.5 k

Additional Paid-in Capital

342 m435.2 m439.1 m441.3 m445.7 m529.6 m532.6 m537.1 m546.3 m552.8 m563.2 m589.9 m668.8 m674 m

Retained Earnings

(280.3 m)(306.6 m)(317.3 m)(324.5 m)(342.5 m)(348.7 m)(343.1 m)(369.1 m)(387.8 m)(408.6 m)(458.2 m)(467.7 m)(555.5 m)(562.1 m)

Total Equity

62.2 m181 m193.4 m171.2 m162.1 m147 m105.9 m123.5 m113.1 m111.5 m

Financial Leverage

1.4 x1.1 x1.2 x1.2 x1.3 x1.3 x1.4 x1.3 x1.5 x1.3 x

Inovio Pharmaceuticals Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(66.1 m)(36.1 m)(29.1 m)(73.7 m)(88.2 m)

Depreciation and Amortization

2.1 m1.6 m1.9 m3.1 m1.9 m

Accounts Receivable

(2.5 m)499.2 k(4.5 m)(8.5 m)9.8 m

Inventories

(229.7 k)(160.5 k)(119.3 k)(831.8 k)

Accounts Payable

2.2 m1.5 m6.5 m6.4 m2.8 m

Cash From Operating Activities

(15.4 m)(29.8 m)(12.4 m)(62.6 m)(63.2 m)

Cash From Investing Activities

(9.2 m)(35.8 m)(54.8 m)16.3 m(27.8 m)

Cash From Financing Activities

52.7 m72.5 m84.4 m7.8 m95.7 m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(30.9 m)(10.8 m)(10.7 m)(7.2 m)(10.6 m)(6.2 m)5.6 m(8 m)(18.7 m)(20.8 m)(32.4 m)(39 m)

Depreciation and Amortization

1.3 m2.6 m

Accounts Receivable

2.9 m1.6 m3.3 m5.6 m11 m11.2 m10.4 m17.5 m9.9 m855.4 k4.3 m

Accounts Payable

5.3 m4.7 m4.4 m6.1 m10.5 m12.1 m12.7 m16.2 m14.5 m(6.4 m)(9.4 m)

Cash From Operating Activities

(12.6 m)(31.6 m)

Cash From Investing Activities

26.8 m20.8 m

Cash From Financing Activities

(506.4 k)2.1 m

Inovio Pharmaceuticals Ratios

USDY, 2018

Financial Leverage

1.3 x
Report incorrect company information

Inovio Pharmaceuticals Operating Metrics

FY, 2016

Patents Issued

620
Report incorrect company information